Overview

A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

This study is conducted to evaluate the safety and tolerability of the drug product sNN0029, containing the growth factor VEGF165, when administered directly into one of the fluid filled cavities in the brain using an implanted catheter and an implanted SynchroMed® II pump. Patients with Amyotrophic Lateral Sclerosis will be enrolled.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Newron Sweden AB

Collaborators:

ICON Clinical Research
Medtronic